The new project is expected to help the company in meeting the growing demand for its manufacturing services, which have quadrupled their revenues in the past four years.
The company said that its extensive C. diff patent estate now includes more than 25 US and international patents. Currently, the company is in preclinical development of SYN-004,
First study in the Phase III NSCLC programme, the PACIFIC trial is designed to evaluate progression free survival and overall survival of MEDI4736 compared to placebo in patients
The multi-center, randomized, placebo-controlled, Phase IIb study, will be conducted primarily in the US and patient enrollment is expected to begin in the near future. The study is
The Phase Ib trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of three months and 18
As part of the deal, Capricor has been granted an exclusive world-wide license, with the right to sublicense, IP related to exosomes originating from cardiosphere-derived cells (CDCs). The
The patent, which has terms that expire no earlier than 2031, covers the company’s unique formulation in conjunction with anti-obesity agents for the reduction of body weight in
The agreement covers Germany, UK, France, Belgium, Luxemburg, Ireland, and Austria, and etoricoxib is marketed under the brand name of Arcoxia in these markets. Grünenthal chief commercial officer
The agreement will allow the discovery and development of potential oral first-in-class compounds that inhibit Macrophage Migration Inhibitory Factor (MIF), a major regulatory cytokine that has been linked
Oxford, which is focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, secured the rights under its existing strategic collaboration with Amgen. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.